Oral ensitrelvir was significantly more effective than placebo for preventing COVID-19 infection in uninfected at-risk adults who had exposure to those infected, based on data from a phase 3 trial presented at the 2025 Conference on Retroviruses and Opportunistic Infections. Ensitrelvir, an oral SARS-CoV-2 3CL protease inhibitor, is approved in Japan for the treatment of […]
The post Ensitrelvir Shows Promise Preventing COVID-19 Post Exposure first appeared on News Health.
Author : News Health
Publish date : 2025-03-14 16:32:00
Copyright for syndicated content belongs to the linked Source.